Cytokinetics, Incorporated $CYTK Shares Acquired by Handelsbanken Fonder AB

Handelsbanken Fonder AB raised its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 63.8% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 405,000 shares of the biopharmaceutical company’s stock after purchasing an additional 157,700 shares during the period. Handelsbanken Fonder AB’s holdings in Cytokinetics were worth $34,502,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of CYTK. Bank of Montreal Can grew its stake in shares of Cytokinetics by 1.2% during the 4th quarter. Bank of Montreal Can now owns 13,292 shares of the biopharmaceutical company’s stock valued at $845,000 after buying an additional 160 shares during the period. Kennedy Capital Management LLC boosted its holdings in Cytokinetics by 1.2% in the fourth quarter. Kennedy Capital Management LLC now owns 13,183 shares of the biopharmaceutical company’s stock valued at $838,000 after acquiring an additional 162 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in Cytokinetics by 46.0% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 543 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 171 shares during the last quarter. Vident Advisory LLC grew its position in Cytokinetics by 1.4% during the fourth quarter. Vident Advisory LLC now owns 16,455 shares of the biopharmaceutical company’s stock valued at $1,046,000 after acquiring an additional 234 shares during the period. Finally, CIBC Private Wealth Group LLC increased its stake in Cytokinetics by 6.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 3,723 shares of the biopharmaceutical company’s stock worth $237,000 after acquiring an additional 239 shares during the last quarter.

Cytokinetics Stock Performance

Cytokinetics stock opened at $76.45 on Wednesday. The firm has a market capitalization of $9.51 billion, a PE ratio of -10.59 and a beta of 0.38. Cytokinetics, Incorporated has a one year low of $33.17 and a one year high of $88.31. The stock’s 50 day moving average price is $79.10 and its 200 day moving average price is $71.15.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.63) by $0.13. The firm had revenue of $28.62 million during the quarter, compared to analyst estimates of $17.59 million. The firm’s revenue was down 57.1% compared to the same quarter last year. During the same period last year, the business earned ($1.12) EPS. On average, analysts forecast that Cytokinetics, Incorporated will post -6 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Sung Lee sold 1,112 shares of the firm’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $87.79, for a total transaction of $97,622.48. Following the completion of the sale, the executive vice president directly owned 63,221 shares of the company’s stock, valued at approximately $5,550,171.59. This trade represents a 1.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Fady Ibraham Malik sold 3,500 shares of the business’s stock in a transaction on Tuesday, July 21st. The stock was sold at an average price of $80.59, for a total transaction of $282,065.00. Following the completion of the transaction, the executive vice president owned 153,902 shares in the company, valued at $12,402,962.18. This represents a 2.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 122,679 shares of company stock valued at $9,701,754 in the last 90 days. Company insiders own 2.60% of the company’s stock.

Key Headlines Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: HC Wainwright raised its earnings forecasts and maintained a Buy rating. The analyst improved its Q3 2026 EPS estimate to $(1.65) from $(1.80), Q4 to $(1.55) from $(1.86), and full-year 2026 to $(6.38) from $(6.86). HC Wainwright also retained a $140 price target, well above recent trading levels, signaling confidence in Cytokinetics’ development pipeline and future prospects.
• Positive Sentiment: Other analysts have recently increased their price targets. Citizens JMP raised its target to $110, Truist Financial lifted its target to $112, and UBS upgraded the stock to Buy with a $115 target. The analyst consensus remains “Moderate Buy,” with an average target of approximately $101.15. Cytokinetics Price Target Raised to $110 Cytokinetics Price Target Raised to $112
• Neutral Sentiment: Reported short-interest data showed no measurable short position. The filing listed short interest at zero shares and a zero-day short-interest ratio, but the reported percentage change was unavailable. Consequently, the data provides little actionable information about potential short-covering or bearish positioning.
• Negative Sentiment: CEO Robert Blum sold 7,500 shares worth approximately $575,700. The transaction reduced his direct holdings by 1.95%, which can create a modest negative signal for investors. However, the sale was executed under a pre-arranged Rule 10b5-1 trading plan, making it less indicative of a discretionary bearish view. Insider Selling: Cytokinetics CEO Sells 7,500 Shares

Analyst Ratings Changes

Several equities analysts have recently weighed in on CYTK shares. Wall Street Zen lowered Cytokinetics from a “hold” rating to a “sell” rating in a research note on Saturday. Citizens Jmp lifted their price target on shares of Cytokinetics from $105.00 to $110.00 and gave the company a “market outperform” rating in a research report on Friday, August 7th. Wells Fargo & Company boosted their price objective on shares of Cytokinetics from $95.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. JPMorgan Chase & Co. raised their target price on shares of Cytokinetics from $92.00 to $97.00 and gave the company an “overweight” rating in a research note on Tuesday, May 12th. Finally, Royal Bank Of Canada reduced their target price on shares of Cytokinetics from $117.00 to $112.00 and set an “outperform” rating on the stock in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $101.15.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.